Dr. Jan Skvarka reports
TRILLIUM THERAPEUTICS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT
Trillium Therapeutics Inc. has regained compliance with the Nasdaq Capital Market minimum bid price requirement, and the matter is now closed.
According to the letter received from the Nasdaq listing qualifications department, the closing bid price of the company's common stock has been at $1 per share or greater for a minimum of 10 consecutive days, and the company has regained compliance with the minimum bid price requirement set forth in Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market.
"We are pleased that this compliance technicality is behind us. More importantly, however, we are very excited about the highly enthusiastic response to our recent data update and changes to strategic direction," commented Dr. Jan Skvarka, president and chief executive officer of Trillium. "We believe that we have a leading CD47 portfolio, which comprises two unique and differentiated molecules, and that both TTI-621 and TTI-622 have the potential to be best-in-class anti-CD47 drugs."
About Trillium Therapeutics Inc.
Trillium Therapeutics is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company's two clinical programs, TTI-621 and TTI-622, target CD47, a "do-not-eat" signal that cancer cells frequently use to evade the immune system.
We seek Safe Harbor.
© 2020 Canjex Publishing Ltd. All rights reserved.